Showing results (51-60 of 58) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
The Lancet. Infectious Diseases|July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trialGary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.The New England Journal of Medicine|August 4, 2021
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19Meagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, et al.Medrxiv : the Preprint Server for Health Sciences|June 23, 2021
Subcutaneous REGEN-COV Antibody Combination for Covid-19 PreventionMeagan P O'Brien, Eduardo Forleo-Neto, Bret J Musser, et al.JAMA|January 14, 2022
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical TrialMeagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.Medrxiv : the Preprint Server for Health Sciences|June 23, 2021
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical TrialMeagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, et al.Pageof 6